摘要
色素上皮衍生因子(PEDF)是属于丝氨酸蛋白酶抑制剂、丝氨酸蛋白酶抑制剂超家族的糖蛋白。 它首先被鉴定为人视网膜色素上皮细胞分泌的神经元分化因子,然后被发现是哺乳动物眼中最有效的病理性血管生成抑制剂。 最近,PEDF不仅用于抑制血管壁细胞、T细胞和巨噬细胞和脂肪细胞中的氧化应激和炎症反应,而且还能发挥抗血栓和抗纤维化的特性,从而保护各种心脏代谢疾病和相关并发症的发展和进展。 此外,累积证据表明,循环PEDF水平可能是这些破坏性疾病严重程度和预后的生物标志物。 内脏肥胖和胰岛素抵抗的受试者数量在增加,代谢综合征及其相关并发症,如糖尿病、非酒精性脂肪肝疾病/非酒精性脂肪性肝炎和动脉粥样硬化性心血管疾病是越来越多的健康挑战。 因此,在本研究中,我们回顾了PEDF在肥胖和代谢障碍、心血管疾病、糖尿病眼和肾脏并发症、肝病和生殖系统疾病中的病理生理作用,并讨论了调节PEDF在预防这些心脏代谢障碍中的表达和作用的潜在临床实用性。 我们还提到PEDF的临床价值作为心脏代谢并发症的生物标志物。
关键词: 心血管疾病,炎症,代谢紊乱,氧化应激,PEDF,视网膜病变,糖尿病肾病。
Current Medicinal Chemistry
Title:Pigment Epithelium-Derived Factor: A Novel Therapeutic Target for Cardiometabolic Diseases and Related Complications
Volume: 25 Issue: 13
关键词: 心血管疾病,炎症,代谢紊乱,氧化应激,PEDF,视网膜病变,糖尿病肾病。
摘要: Pigment epithelium-derived factor (PEDF) is a glycoprotein that belongs to the superfamily of serine protease inhibitors, serpins. It was first identified as a neuronal differentiating factor secreted by human retinal pigment epithelial cells, and then found to be the most potent inhibitor of pathological angiogenesis in mammalian eyes. Recently, PEDF has been shown not only to suppress oxidative stress and inflammatory reactions in vascular wall cells, T cells and macrophages, and adipocytes, but also to exert antithrombotic and anti-fibrotic properties, thereby protecting against the development and progression of various cardiometabolic diseases and related complications. Furthermore, accumulating evidence has suggested that circulating PEDF levels may be a biomarker of severity and prognosis of these devastating disorders. Number of subjects with visceral obesity and insulin resistance is increasing, and the metabolic syndrome and its related complications, such as diabetes, nonalcoholic fatty liver disease/non-alcoholic steatohepatits, and atherosclerotic cardiovascular disease are a growing health challenge. Therefore, in this study, we review the pathophysiological role of PEDF in obesity and metabolic disorders, cardiovascular disease, diabetic eye and kidney complications, liver diseases, and reproductive system disorders, and discuss the potential clinical utility of modulating the expression and actions of PEDF for preventing these cardiometabolic disorders. We also refer to the clinical value of PEDF as a biomarker in cardiometabolic complications.
Export Options
About this article
Cite this article as:
Pigment Epithelium-Derived Factor: A Novel Therapeutic Target for Cardiometabolic Diseases and Related Complications, Current Medicinal Chemistry 2018; 25 (13) . https://dx.doi.org/10.2174/0929867324666170608103140
DOI https://dx.doi.org/10.2174/0929867324666170608103140 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diabetes and Antioxidants: Myth or Reality?
Current Vascular Pharmacology Protein Aggregation and Self Assembly in Health and Disease
Current Proteomics Research Progress on Pathogenesis of Obesity-Induced Insulin Resistance and Its Therapeutic Targets: PPARα/γ
Current Signal Transduction Therapy Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry Quality Control of Fingerprint of Radix Astragali by High-Performance Liquid Chromatography Coupled with Chemometric Methods
Current Pharmaceutical Analysis Is Atorvastatin Superior to Other Statins? Analysis of the Clinical Trials with Atorvastatin Having Cardiovascular Endpoints
Reviews on Recent Clinical Trials Identification of New Susceptibility Genes for Type 1 Diabetes: An Update
Current Immunology Reviews (Discontinued) Adult Stem Cells and Extracellular Vesicles in Acute and Chronic Kidney Injury
Current Regenerative Medicine (Discontinued) Emerging Role for Antioxidant Therapy in Protection Against Diabetic Cardiac Complications: Experimental and Clinical Evidence for Utilization of Classic and New Antioxidants
Current Cardiology Reviews Biological and Pharmacological Activities of Iridoids: Recent Developments
Mini-Reviews in Medicinal Chemistry Stenting Renal Artery Stenosis: What is the Fuss All About?
Reviews on Recent Clinical Trials The Role of Diabetes in Molecular Pathogenesis of Cancer
Current Signal Transduction Therapy Hypertension in the Elderly: An Evidence-based Review
Current Pharmaceutical Design Modulation of Nitric Oxide Pathway by Multiligands/RAGE Axis: A Crossing Point on the Road to Microvascular Complication in Diabetes
Current Enzyme Inhibition Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design Current Approaches to Prevention of Contrast Induced Acute Kidney Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Are the Myokines the Mediators of Physical Activity-Induced Health Benefits?
Current Pharmaceutical Design Pleiotropic Effects of Fenofibrate
Current Pharmaceutical Design Meta-analysis and Approach of the Real Impact of Anorexigenic Drugs in the Obesity in Humans: The Last Five Years of the Randomized Studies
Current Diabetes Reviews A2A Adenosine Receptor and its Modulators: Overview on a Druggable GPCR and on Structure-Activity Relationship Analysis and Binding Requirements of Agonists and Antagonists
Current Pharmaceutical Design